As of 2026-04-03, the Intrinsic Value of Bioventus Inc (BVS) is 16.47 USD. This Bioventus valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 8.97 USD, the upside of Bioventus Inc is 83.70%.
The range of the Intrinsic Value is 10.48 - 33.79 USD
Based on its market price of 8.97 USD and our intrinsic valuation, Bioventus Inc (BVS) is undervalued by 83.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 10.48 - 33.79 | 16.47 | 83.7% |
| DCF (Growth 10y) | 13.70 - 40.28 | 20.59 | 129.5% |
| DCF (EBITDA 5y) | 7.71 - 9.89 | 8.75 | -2.4% |
| DCF (EBITDA 10y) | 10.90 - 14.64 | 12.64 | 40.9% |
| Fair Value | 1.37 - 1.37 | 1.37 | -84.76% |
| P/E | 9.32 - 14.11 | 11.02 | 22.9% |
| EV/EBITDA | 5.20 - 8.48 | 7.21 | -19.6% |
| EPV | 6.79 - 10.31 | 8.55 | -4.7% |
| DDM - Stable | 2.59 - 10.57 | 6.58 | -26.6% |
| DDM - Multi | 7.09 - 23.31 | 10.97 | 22.3% |
| Market Cap (mil) | 745.86 |
| Beta | 0.52 |
| Outstanding shares (mil) | 83.15 |
| Enterprise Value (mil) | 998.20 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.36% |
| Cost of Debt | 8.32% |
| WACC | 8.07% |